CRMD CorMedix Inc

Price (delayed)
$5.02 -1.18% 1D
Market cap
$399.28M
P/E ratio
6.69
Dividend per share
N/A
EPS
$0.75
Enterprise value
$189.55M

FullRatio score

?
Relative Growth 35
Relative Strength 17
Relative Valuation 88
Relative Profitability 83

Highlights

CorMedix's equity has increased by 23% YoY
The company's debt fell by 2.4% YoY
The revenue has soared by 92% YoY but it has contracted by 11% from the previous quarter
The gross profit has soared by 61% YoY but it has contracted by 16% from the previous quarter
The EPS has dropped by 68% since the previous quarter and by 67% year-on-year
CorMedix's net income has plunged by 66% from the previous quarter and by 61% YoY

Company profile

CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its ...

Sector
Healthcare
Industry
Biotechnology
Peers
BDX EBS UTMD

Key stats

What are the main financial stats of CRMD

Market

Name
Current
Shares outstanding
79.54M
Market cap
$399.28M
Enterprise value
$189.55M

Earnings

Name
Current
Revenue
$412.49M
Gross profit
$319.56M
Operating income
$159.08M
Net income
$63.89M
EBIT
$136.19M
EBITDA
$178.24M
Free cash flow
$307.86M

Per share

Name
Current
EPS
$0.75
EPS diluted
$0.6
Free cash flow per share
$3.92
Book value per share
$5.92
Revenue per share
$5.26
TBVPS
$6.88

Valuations

Name
Current
Price to earnings (P/E)
6.69
Price to book (P/B)
0.85
Price to sales (P/S)
0.95
PEG
N/A
EV/EBIT
1.39
EV/EBITDA
1.06
EV/Sales
0.46

Margins

Name
Current
EBITDA margin
43.2%
Gross margin
77.5%
Net margin
15.5%
Operating margin
38.6%

Balance sheet

Name
Current
Total assets
$917.75M
Total liabilities
$456.04M
Debt
$145.42M
Equity
$461.71M
Working capital
$295.7M

Liquidity

Name
Current
Debt to equity
0.31
Current ratio
2.43
Quick ratio
2.08
Net debt/EBITDA
-1.18

Efficiency

Name
Current
Return on assets
7.4%
Return on equity
14.5%
Return on invested capital
65.1%
Return on capital employed
19.2%
Return on sales
33%

Dividend

Name
Current
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRMD stock price

How has the CorMedix stock price performed over time
Intraday
-1.18%
1 week
7.73%
1 month
-33.69%
1 year
-48.35%
YTD
-56.84%
QTD
-34.81%

Financial performance

How have CorMedix's revenue and profit performed over time
Revenue
$412.49M
Gross profit
$319.56M
Operating income
$159.08M
Net income
$63.89M
Gross margin
77.5%
Net margin
15.5%
The revenue has soared by 92% YoY but it has contracted by 11% from the previous quarter
The company's net margin has shrunk by 80% YoY and by 62% QoQ
CorMedix's net income has plunged by 66% from the previous quarter and by 61% YoY
The gross profit has soared by 61% YoY but it has contracted by 16% from the previous quarter

Price vs fundamentals

How does CRMD's price correlate with its fundamentals

Growth

What is CorMedix's growth rate over time

Valuation

What is CorMedix stock price valuation
P/E
6.69
P/B
0.85
P/S
0.95
EV/EBIT
1.39
EV/EBITDA
1.06
EV/Sales
0.46
The EPS has dropped by 68% since the previous quarter and by 67% year-on-year
The price to earnings (P/E) is 25% higher than the last 4 quarters average of 5.4
The P/B is 73% below the 5-year quarterly average of 3.2 and 43% below the last 4 quarters average of 1.5
CorMedix's equity has increased by 23% YoY
The price to sales (P/S) is 100% lower than the 5-year quarterly average of 1303.8 and 43% lower than the last 4 quarters average of 1.7
The revenue has soared by 92% YoY but it has contracted by 11% from the previous quarter

Efficiency

How efficient is CorMedix business performance
The ROA has plunged by 86% YoY and by 67% from the previous quarter
CorMedix's ROE has plunged by 82% YoY and by 67% from the previous quarter
The return on sales has declined by 34% year-on-year and by 26% since the previous quarter
The company's return on invested capital fell by 30% YoY and by 19% QoQ

Dividends

What is CRMD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRMD.

Financial health

How did CorMedix financials performed over time
CRMD's total assets is 101% higher than its total liabilities
The quick ratio rose by 30% YoY but it fell by 7% QoQ
CRMD's current ratio is up by 25% year-on-year but it is down by 5% since the previous quarter
The company's debt is 69% lower than its equity
CorMedix's debt to equity has decreased by 23% YoY
CorMedix's equity has increased by 23% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.